FDA Head Drug Regulator George Tidmarsh Resigns Amid Concerns Tied to Lupkynis

George Tidmarsh, the head drug regulator at the U.S. Food and Drug Administration (FDA), has resigned from his position. His departure follows concerns surrounding conduct related to Lupkynis, a drug used in the treatment of lupus nephritis. This resignation marks another instance of high-profile changes within U.S. regulatory agencies.

The circumstances surrounding Tidmarsh’s exit have drawn attention due to its connection with Lupkynis, a medication approved for managing lupus nephritis, a serious kidney condition associated with systemic lupus erythematosus. While specific details regarding the concerns have not been disclosed, the timing of his resignation has raised questions about internal operations and oversight within the FDA. This development adds to ongoing scrutiny of leadership transitions across federal agencies in recent years.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: November 4, 2025

Author

GOAI